News & Media

Keep up to date with all of our latest news.

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy All…

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy All…

SparingVision Conference Participation in H1 2026

SparingVision Conference Participation in H1 2026 Paris, 11 December 2025 – SparingVision (“the Company”), a…

SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial

SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to…

SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025

SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025 Paris, 9 October 2025…

SparingVision to Showcase its Gene-Agnostic Gene Therapy Programs at Upcoming Conferences

SparingVision to Showcase its Gene-Agnostic Gene Therapy Programs at Upcoming Conferences Paris, 28 August…

SparingVision Conference Participation in H2 2025

SparingVision Conference Participation in H2 2025 Paris, 2 July 2025 – SparingVision (“the Company”),…

SparingVision appoints Dr. Kali Stasi as Chief Medical Officer

SparingVision appoints Dr. Kali Stasi as Chief Medical Officer Experienced global leader in ophthalmology…

SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025

SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025 Favorable…

SparingVision Announces Favorable Safety Update from PRODYGY Trial at ARVO 2025

SparingVision Announces Favorable Safety Update from PRODYGY Trial at ARVO 2025 Preliminary safety data…

SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD

SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary…

News & Media Menu

PARTNERS

01

Home

02

Technology

03

Patients

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. Further information: https://developers.cloudflare.com/fundamentals/reference/policies-compliances/cloudflare-cookies/#__cf_bm-cookie-for-cloudflare-bot-products
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Analytics" category.
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Necessary" category.
CookieLawInfoConsent	6 months	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
vuid	1 year 1 month 4 days	We embed videos from our official Vimeo channel. When you press play Vimeo may set cookies to enable the video to play and maintain the security of its service. These cookies do not directly identify anyone. If you have a Vimeo account and are logged in, Vimeo may set cookies for analytics and advertising purposes and collect data linked to your Vimeo account when you visit a page containing a Vimeo video. For more information, see the Vimeo cookies policy.